Repligen Corporation (RGEN): Price and Financial Metrics
Repligen Corporation (RGEN)
Today's Latest Price: $181.43 USD
Updated Nov 25 4:00pm
Add RGEN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
RGEN Stock Summary
- With a price/earnings ratio of 217.8, Repligen Corp P/E ratio is greater than that of about 96.42% of stocks in our set with positive earnings.
- The price/operating cash flow metric for Repligen Corp is higher than 97.12% of stocks in our set with a positive cash flow.
- RGEN's price/sales ratio is 29.19; that's higher than the P/S ratio of 93.32% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Repligen Corp are SWI, OMCL, DT, VRNT, and GLOB.
- Visit RGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.repligen.com.
RGEN Stock Price Chart Interactive Chart >
RGEN Price/Volume Stats
| Current price | $181.43 | 52-week high | $212.55 |
| Prev. close | $179.15 | 52-week low | $78.41 |
| Day low | $178.54 | Volume | 259,700 |
| Day high | $183.75 | Avg. volume | 517,036 |
| 50-day MA | $171.63 | Dividend yield | N/A |
| 200-day MA | $133.91 | Market Cap | 9.55B |
Repligen Corporation (RGEN) Company Bio
Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.
RGEN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $181.43 | $18.82 | -90% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Repligen Corp. To summarize, we found that Repligen Corp ranked in the 11th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Repligen Corp, consider:
- The compound growth rate in the free cash flow of Repligen Corp over the past 5.64 years is 0.24%; that's higher than 58.76% of free cash flow generating stocks in the Healthcare sector.
- 97% of the company's capital comes from equity, which is greater than 89.03% of stocks in our cash flow based forecasting set.
- The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than merely 10.93% of the free cash flow producing stocks we're observing.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -90% |
| 1% | -90% |
| 2% | -90% |
| 3% | -90% |
| 4% | -90% |
| 5% | -90% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RGEN, try BHC, VAR, QGEN, SIGA, and COO.
Loading social stream, please wait...